hmm.. this is an excerpt from the announcement where she was...

hmm.. this is an excerpt from the announcement where she was hired:

"Dr Laeufle will lead the Company’s global clinical development, regulatory and medical monitoring
activities, replacing Dr Mark Marino who is stepping down from his position.
As a board-certified surgical oncologist and a scientist, Dr Laeufle has extensive clinical development
experience in immuno-oncology studies from Phase 1 to Phase 3 in breast and gastrointestinal cancers
registration pathways.

Dr Laeufle brings deep experience to the Company, having held senior level clinical
development, leadership and senior medical positions at top tier pharmaceutical companies, including
Hoffman-La Roche AG, and Novartis Pharmaceuticals Corp. Most recently she was the CMO at leading
oncolytic virus company Oncolytics Biotech in San Diego CA, where she will be based.

Dr Laeufle holds Medical Doctor and Doctor of Philosophy degrees from the Albert Ludwig University
Freiburg i.Br. Germany. Her PhD subject was expression of neu/c-erbB-2 (HER-2) in human brain tumors. "

If anything you infer think that the hervaxx product has done what she was brought in to help it do given her focus in gastrointestinal cancers and also focusing on HER-2 in her thesis. I don't think that's too far of a stretch. I would bet the next CMO has experience in some type of viral oncology field or focus given CF33. Can't see someone retiring after joining a company that soon unless they did what they were supposed to do in the role with a company this small.